Individuals with schizophrenia frequently have impairments in attention. These impairments
have been shown to be related to overall functioning. Some research suggests that Olanzapine
may be associated with improvement in various aspects of attention. The primary purpose of
this study is to determine whether switching from a typical antipsychotic to Olanzapine
improves task engagement. Individuals who taking typical antipsychotics will be randomly
assigned to either 1) remain on their typical antipsychotic medications, or 2) be switched
from their typical antipsychotic medications to Olanzapine. All participants will be enrolled
in a twice-weekly 20 session cognitive training program that is specifically designed to
target attention deficits and promote active engagement. Improvements in attention will be
compared between individuals who remained on their typical antipsychotic medications and
those that were switched to Olanzapine.
Phase:
Phase 3
Details
Lead Sponsor:
VA Connecticut Healthcare System
Collaborators:
Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital Eli Lilly and Company